Growth Hormone Replacement Therapy in Adults: Risks & Benefits
Track
:
Sessions
Program Code:
CMES01-3
Date:
Sunday, June 5, 2011
Time:
7:00 AM to 7:20 AM
EST
Location:
Westin, Grand Ballroom AB
SPEAKER
:
David M. Cook, MD, Oregon Health & Science University Consultant, Novo Nordisk Inc.; Research grant recipient, Indevus Pharmaceuticals; Speaker, Eli Lilly & Co. , Pfizer
Dr. Cook has been involved in clinical and laboratory research since 1969. He received his medical degree in 1963 from St. Louis University. He completed his Medicine residency at the University of Chicago and at the Mayo Clinic in Rochester. He completed his Endocrinology fellowship at the University of Oregon Medical School. Dr. Cook became board certified in Medicine in 1969, and in Endocrinology in 1975.
In collaboration with Dr. Kendall and Dr. Leslie Rees, St. Bartholomew's Hospital London, England, the first clinically useful assay for plasma ACTH was developed. Since that time publications and research have been focused on pituitary-adrenal clinical problems, especially Cushing's Syndrome and Cushing's Disease.
Dr. Cook's clinical interest has included other pituitary problems, including those of too much and too little growth hormone and the impact of these clinical metabolic derangements which include acromegaly and the adult growth hormone deficiency syndrome. The clinical usefulness of cavernous sinus sampling of plasma ACTH for the differential diagnosis of ACTH dependent Cushing's syndrome is one of the products of his interest. More recently, dosing of growth hormone for adults deficient in these hormones has been another focus. National collaborative studies include treatment of acromegalic patients with long acting somatostatin analogues and problems in the diagnosis of growth hormone deficiency in adults.